May 1, 2024
FDA Grants Full Approval to Pfizer’s Tivdak for Advanced Cervical Cancer Treatment
FDA, Pfizer, Tivdak, full approval, advanced cervical cancer, treatment, regulatory tracker
The Closure of Walmart Health Highlights Significant Hurdles for Retail Health Innovators
Walmart Health, retail health, disruptors, challenges, closure, innovation, healthcare, accessibility, competition, patient engagement, healthcare landscape.
Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program
Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.
GSK’s Vaccine Sales Surge Continues, Boosting 2024 Outlook
GSK, GlaxoSmithKline, vaccine sales, 2024 forecasts, pharmaceutical industry, revenue growth, COVID-19 vaccines, Shingrix, healthcare sector
Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database
FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.
Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology
Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.
Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics
Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors
Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity
Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.